Two Sigma Investments
MAZE

Two Sigma Investments’s Maze Therapeutics MAZE Stock Holding History

Two Sigma Investments’s Portfolio MAZE Stock Details MAZE Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		$473K Buy
15,845
+8,600
+119% +$380K ﹤0.01% 3773
2025
Q4 		$300K Sell
7,245
-3,905
-35% -$134K ﹤0.01% 3572
2025
Q3 		$289K Buy
+11,150
New +$188K ﹤0.01% 3232

Other funds holding MAZE

FLSM
Frazier Life Sciences Management Palo Alto, California $3.89B AUM 201.1% 1-Year Est. Return
TGI
TRV GP IV Boston, Massachusetts $267M AUM 965.83% 1-Year Est. Return
AVM
Arch Venture Management Chicago, Illinois $677M AUM 322.07% 1-Year Est. Return
DTC
Deep Track Capital Greenwich, Connecticut $6.12B AUM 144% 1-Year Est. Return
Janus Henderson Group
Janus Henderson Group London, United Kingdom $209B AUM 37.72% 1-Year Est. Return
PBA
Paradigm Biocapital Advisors New York $4.89B AUM 251.12% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
ACM
AH Capital Management Menlo Park, California $1.29B AUM 26.81% 1-Year Est. Return
VA
VR Adviser New York $2.68B AUM 422.73% 1-Year Est. Return
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM

Two Sigma Investments's MAZE Position: Q1 2026 in Review

Two Sigma Investments increased its Maze Therapeutics (MAZE) stake by 119% in Q1 2026, buying an estimated $380K and bringing the position to 15,845 shares worth $473K. The position accounts for ﹤0.01% of the portfolio, ranked #3773.

Two Sigma Investments first reported a position in MAZE in Q3 2025 and has held it in 3 quarters since. 165 funds tracked by Wall St. Rank hold MAZE as of Q1 2026.

  • Two Sigma Investments held 15,845 shares of Maze Therapeutics worth $473K as of Q1 2026.
  • Two Sigma Investments bought 8,600 Maze Therapeutics shares in Q1 2026, an estimated $380K.
  • Maze Therapeutics made up ﹤0.01% of Two Sigma Investments's portfolio in Q1 2026, its #3773 holding.
  • Two Sigma Investments first reported a position in Maze Therapeutics in Q3 2025 and has held it in 3 quarters since.
  • 165 funds tracked by Wall St. Rank held Maze Therapeutics as of Q1 2026.

Based on Two Sigma Investments's 13F filing for Q1 2026, filed 15 May 2026.